Kan biosys Revenue and Competitors
Estimated Revenue & Valuation
- Kan biosys's estimated annual revenue is currently $27M per year.
- Kan biosys's estimated revenue per employee is $155,000
Employee Data
- Kan biosys has 174 Employees.
- Kan biosys grew their employee count by 64% last year.
Kan biosys's People
| Name | Title | Email/Phone |
|---|
Kan biosys Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $23.1M | 149 | -4% | N/A | N/A |
#2 | $42.2M | 272 | 18% | N/A | N/A |
#3 | $27M | 174 | 33% | N/A | N/A |
#4 | $27M | 174 | 64% | N/A | N/A |
#5 | $22.9M | 148 | 20% | N/A | N/A |
#6 | $46.5M | 300 | 10% | N/A | N/A |
#7 | $29.3M | 189 | 9% | N/A | N/A |
#8 | $47M | 303 | 24% | N/A | N/A |
#9 | $30.8M | 199 | 24% | N/A | N/A |
#10 | $33.8M | 218 | -17% | N/A | N/A |
What Is Kan biosys?
Kan biosys - we build trust with focussed technology. A specialized agri-biotech company with a vision to go global aiming for high yields, reducing toxins and residues. Innovative certified products for nutrition, pest and soil health management. Award winning bio-solutions, biofertilizers and biopesticides used in 8 countries.
keywords:N/A
N/A
Total Funding
174
Number of Employees
$27M
Revenue (est)
64%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Kan biosys News
... Camson Biotechnologies Ltd, Andermatt Biocontrol AG, Kan Biosys Pvt. Ltd., Futureco Bioscience S.A., Kilpest India Ltd, BioSafe Systems,...
... EuroChem Agro GmbH; Gujarat State Fertilizers & Chemicals Limited; Kan Biosys Pvt. Ltd.; Kiwa Bio-Tech Products Group Corporation;...
Kan Biosys (India); Mapleton Agri Biotech Pty Ltd (Australia); Seipasa (Spain); AgriLife (India); Manidharma Biotech Pvt Ltd (India); Biomax...
Other Companies in Pune
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $24.4M | 174 | 72% | N/A |
#2 | $24.4M | 174 | 5% | N/A |
#3 | $24.4M | 174 | -2% | N/A |
#4 | $30.6M | 174 | 10% | N/A |
#5 | $24.4M | 174 | 11% | N/A |